Answers to ETCAMAH questions are right here
Enroll in My ETCAMAH Support for even more information
CLOSE ALL
About ETCAMAH
COLLAPSE ALL
ETCAMAH is a prescription medicine used in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that:
- has worsened or spread to other parts of the body (advanced or metastatic breast cancer), and
- has an estrogen receptor-1 (ESR1) mutation detected during treatment with an aromatase inhibitor and a CDK4/6 inhibitor
Your healthcare provider will perform a test to make sure that ETCAMAH is right for you.
ETCAMAH was FDA approved for this use based on a clinical study that measured time to cancer growth or spread (progression-free survival). ETCAMAH is still being studied to confirm these results.
It is not known if ETCAMAH is safe and effective in children.
HR-positive, HER2-negative metastatic breast cancer is the most common subtype of breast cancer, affecting more than 70% of patients. It means that the cancer cells have receptors that attach to hormones like estrogen or progesterone, helping the cancer grow.
Metastatic breast cancer is a type of cancer that has gotten worse or spread to other parts of the body.
ETCAMAH is approved for adults with ESR1-mutated, HR-positive, HER2-negative metastatic breast cancer. Your doctor may replace your first hormone therapy with ETCAMAH if you test positive for the ESR1 mutation. Your healthcare provider will also perform a test to make sure that ETCAMAH is right for you.
Certain hormones, like estrogen, help cancer grow or spread.
Hormone therapies work by either lowering the levels of these hormones or blocking the hormone signaling caused by them.
In the case of ETCAMAH, it blocks the hormones telling the cancer to grow and breaks down the hormone receptors that signal cancer cell growth.
Talk to your doctor if you experience any side effects with ETCAMAH. They may offer tips or medications to help with certain side effects.
You may report side effects related to AstraZeneca products
.
The recommended dosage of ETCAMAH is one pill taken by mouth once daily, with or without food, at around the same time each day. It's important to take ETCAMAH exactly as your care team has instructed.
Click below to see the full information on how to take ETCAMAH.
Selective estrogen receptor degraders, or SERDs, are a type of hormone therapy used to treat breast cancer.
These drugs keep the hormone estrogen from binding to the hormone receptors inside the cells and block the effects of estrogen in the body.
ETCAMAH is a next-generation oral SERD, which means it is taken by mouth. This drug works in two ways, it blocks the estrogen signals and breaks down estrogen receptors. This helps prevent the estrogen hormone from telling the cancer to grow.
Monitoring for ESR1 mutations
COLLAPSE ALL
Ask your doctor about proactive monitoring for the ESR1 mutation while you are on your first treatment for metastatic breast cancer with a CDK4/6 inhibitor. This can help identify treatment resistance before it can become a problem.
Talk to your care team about monitoring for ESR1 mutations if you are on your first hormone therapy (anastrozole, exemestane, or letrozole) and a CDK4/6 inhibitor for metastatic breast cancer.
Cost, coverage, & financial help
COLLAPSE ALL
Support programs are available through AstraZeneca Access 360™.
Simply call 1-844-ASK-A360 (1-844-275-23601-844-275-2360) Monday–Friday, 8 AM–6 PM ET, or visit www.MyAccess360.com for more information.
Yes, join our patient support program for email updates, helpful resources, and financial help.
Yes. Agents are available through the AstraZeneca Access 360™, at 1-844-ASK-A360 (1-844-275-23601-844-275-2360), Monday–Friday, 8 AM–6 PM ET.
Get financial support with ETCAMAH
AstraZeneca Access 360TMJoin My ETCAMAH Support
Patient Support Program
IMPORTANT SAFETY INFORMATION ABOUT ETCAMAH® (camizestrant)
EXPAND
IMPORTANT SAFETY INFORMATION ABOUT ETCAMAH® (camizestrant)
What is the most important information I should know about ETCAMAH?
ETCAMAH can cause serious side effects including:
- Changes in electrical activity of your heart (QTc interval prolongation). Taking ETCAMAH in combination with ribociclib or other QTc interval prolonging drugs may cause life-threatening heart rhythm problems and may lead to death. Before starting and during treatment with ETCAMAH, your healthcare provider will do an electrocardiogram (ECG) to check the electrical activity of your heart and do blood tests to check the blood levels of your body salts (electrolytes). Your healthcare provider will treat abnormal electrolyte levels
- Slow heart rate (bradycardia). Your healthcare provider will check your heart rate frequently during the first 30 days of treatment with ETCAMAH if you have bradycardia (heart rate less than 60 beats per minute) before starting treatment and if you take medicines that lower heart rate
Get medical help right away if you get the following signs or symptoms of QTc prolongation and bradycardia including: dizziness, lightheadedness, fainting, feeling that your heart is pounding or racing (palpitations), shortness of breath, or chest pain.
Your healthcare provider may delay treatment or completely stop treatment with ETCAMAH if you have severe side effects.
Before you take ETCAMAH, tell your healthcare provider if you:
- have any liver-related problems
- have a slow heartbeat (bradycardia)
- have heart problems including irregular heartbeats and QTc prolongation
- are pregnant or plan to become pregnant. ETCAMAH can harm your unborn baby
- Females who are able to become pregnant
- Your healthcare provider will check that you are not pregnant before you start treatment with ETCAMAH
- Use effective non-hormonal birth control (contraception) during treatment with ETCAMAH and for 1 month after the last dose. Talk to your healthcare provider about birth control methods that may be right for you during this time
- Tell your healthcare provider if you become pregnant or think you may be pregnant
- Males with female partners who can become pregnant
- Use effective birth control during treatment with ETCAMAH and for 1 week after your last dose
- are breastfeeding or plan to breastfeed. It is not known if ETCAMAH passes into your breast milk. Do not breastfeed during treatment with ETCAMAH and for 1 week after the last dose. Talk to your healthcare provider about the best way to feed your baby during treatment with ETCAMAH
Tell your healthcare provider about all the medicines you take, including prescription and over‑the‑counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take any heart and blood pressure medicines.
ETCAMAH may affect the way other medicines work, and other medicines may affect how ETCAMAH works. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.
What are the possible side effects of ETCAMAH?
ETCAMAH can cause serious side effects, including:
- See “What is the most important information I should know about ETCAMAH?”
The most common side effects of ETCAMAH in combination with a CDK4/6 inhibitor include:
- decreased white blood cell counts
- decreased red blood cell counts
- decreased platelet counts
- vision problems such as seeing flashes of light, double or blurry vision, light sensitivity, new or increased floaters. Tell your healthcare provider if you have vision problems; you may need to see an eye care specialist
- tiredness
ETCAMAH may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of ETCAMAH.
Call your healthcare provider for medical advice about side effects.
What is ETCAMAH?
ETCAMAH is a prescription medicine used in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that:
- has worsened or spread to other parts of the body (advanced or metastatic breast cancer), and
- has an estrogen receptor-1 (ESR1) mutation detected during treatment with an aromatase inhibitor and a CDK4/6 inhibitor
Your healthcare provider will perform a test to make sure that ETCAMAH is right for you.
- ETCAMAH was FDA approved for this use based on a clinical study that measured time to cancer growth or spread (progression-free survival). ETCAMAH is still being studied to confirm these results
It is not known if ETCAMAH is safe and effective in children.
Please see full Prescribing Information, including Boxed WARNING, and Patient Information for ETCAMAH.
You may report side effects related to AstraZeneca products.
